1. Home
  2. AKBA vs FWRD Comparison

AKBA vs FWRD Comparison

Compare AKBA & FWRD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • AKBA
  • FWRD
  • Stock Information
  • Founded
  • AKBA 2007
  • FWRD 1981
  • Country
  • AKBA United States
  • FWRD United States
  • Employees
  • AKBA N/A
  • FWRD N/A
  • Industry
  • AKBA Biotechnology: Pharmaceutical Preparations
  • FWRD Oil Refining/Marketing
  • Sector
  • AKBA Health Care
  • FWRD Consumer Discretionary
  • Exchange
  • AKBA Nasdaq
  • FWRD Nasdaq
  • Market Cap
  • AKBA 861.7M
  • FWRD 909.4M
  • IPO Year
  • AKBA 2014
  • FWRD 1993
  • Fundamental
  • Price
  • AKBA $3.04
  • FWRD $28.70
  • Analyst Decision
  • AKBA Strong Buy
  • FWRD Buy
  • Analyst Count
  • AKBA 5
  • FWRD 4
  • Target Price
  • AKBA $6.90
  • FWRD $34.67
  • AVG Volume (30 Days)
  • AKBA 4.0M
  • FWRD 627.5K
  • Earning Date
  • AKBA 08-07-2025
  • FWRD 08-11-2025
  • Dividend Yield
  • AKBA N/A
  • FWRD N/A
  • EPS Growth
  • AKBA N/A
  • FWRD N/A
  • EPS
  • AKBA N/A
  • FWRD N/A
  • Revenue
  • AKBA $203,733,000.00
  • FWRD $2,520,908,000.00
  • Revenue This Year
  • AKBA $27.95
  • FWRD $5.57
  • Revenue Next Year
  • AKBA $43.88
  • FWRD $7.43
  • P/E Ratio
  • AKBA N/A
  • FWRD N/A
  • Revenue Growth
  • AKBA 16.75
  • FWRD 35.18
  • 52 Week Low
  • AKBA $1.24
  • FWRD $9.79
  • 52 Week High
  • AKBA $4.08
  • FWRD $40.92
  • Technical
  • Relative Strength Index (RSI)
  • AKBA 34.84
  • FWRD 49.83
  • Support Level
  • AKBA $2.92
  • FWRD $27.83
  • Resistance Level
  • AKBA $3.44
  • FWRD $30.75
  • Average True Range (ATR)
  • AKBA 0.15
  • FWRD 1.67
  • MACD
  • AKBA -0.06
  • FWRD -0.41
  • Stochastic Oscillator
  • AKBA 13.79
  • FWRD 43.87

About AKBA Akebia Therapeutics Inc.

Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics for people with kidney disease. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, in adult patients, HIF-PH inhibitors in preclinical development.

About FWRD Forward Air Corporation

Forward Air Corp is an asset-light freight and logistics company. The company's operating segment includes Expedited Freight, Omni Logistics, and Intermodal and Corporate. The company generates maximum revenue from the Omni Logistics segment. The expedited Freight segment operates a comprehensive national network to provide expedited regional, inter-regional, and national LTL (less-than-truckload) services. It also offers customers local pick-up and delivery and other services including final mile, truckload, shipment consolidation and deconsolidation, warehousing, customs brokerage, and other handling. The Company conducts business in the United States, Canada, and Mexico.

Share on Social Networks: